Comparing Effectiveness Rituximab (MabtheraⓇ) to Other Second-line Biologics for Rheumatoid Arthritis Treatment in Patients Refractory to or Intolerant of First-line Anti-tumor Necrosis Factor Agent: An Observational Study
Yong-Wook Park, Ki-Jo Kim, Hyung-In Yang, Bo Young Yoon, Sang Hyon Kim, Seong-Ho Kim, Jinseok Kim, Ji Seon Oh, Wan-Uk Kim, Yeon-Ah Lee, Jung-Yoon Choe, Min-Chan Park, Sang-Heon Lee
J Rheum Dis. 2017;24(4):227-235. doi: 10.4078/jrd.2017.24.4.227.